ArticleAtherosclerosis plus2025
Plasma apolipoprotein concentrations and occurrence of cardiovascular events in the general population: an exploratory analysis.
Article in Atherosclerosis plus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Myocardial Lipid Metabolism Imbalance: The Pathological Core and Novel Diagnostic-Therapeutic Directions of Cardiovascular Diseases.Journal of biochemical and molecular toxicology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background and aims: The role of many apolipoproteins in cardiovascular disease (CVD) pathophysiology and their predictive potential remains unclear. This study examined the association between plasma concentrations of a broad panel of apolipoproteins and the occurrence of cardiovascular events in a general population. Methods: A nested case-control study was conducted within a cohort from Southwestern France. Baseline concentrations of apolipoproteins A-I, A-II, A-IV, B100, C-I, C-II, C-III, D, E, H, J, L1 and M were analyzed in 65 cases who experienced a cardiovascular event during the follow-up period, and in 65 controls matched for age and sex (mean age 60.9 ± 10.7 years; 66.9 % men; median follow up 9.3 years for controls, 6.2 years for cases). Baseline correlations were assessed using Spearman's coefficients.Logistic regression and partial least squares discriminant analysis (PLS-DA) were used to evaluate associations with the occurrence of cardiovascular events. Results: Concentrations of apolipoproteins A-I, A-IV, C-I, D, H, J and M differed significantly between cases and controls. All expect apoM remained independently associated with cardiovascular events after adjustment for known risk factors. Additionally, PLS-DA revealed that the entire apolipoprotein panel explained 64 % of variance in case-control status with 60 % predictive accuracy, with apolipoproteins D, J, A-IV, H, and C-I contributing the most to group discrimination. Conclusions: This study identifies a novel panel of apolipoproteins (A-I, A-IV, C-I, D, H, and J) whose levels are associated with occurrence of cardiovascular diseases, independently of traditional risk factors. Further research is needed to confirm these findings and explore underlying mechanisms.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.